Clinical Trials Logo

Presbyopia clinical trials

View clinical trials related to Presbyopia.

Filter by:

NCT ID: NCT05901597 Recruiting - Cataract Clinical Trials

Refractive Accuracy of Argos in Conjunction With the Alcon Vision Suite Following Implantation of Presbyopia Correcting IOLs

Start date: May 9, 2023
Phase:
Study type: Observational

The objective is to assess refractive accuracy of the Alcon Vision Suite (with Argos biometer) following Clareon PanOptix and AcrySof Vivity IOL implantation.

NCT ID: NCT05863247 Active, not recruiting - Presbyopia Clinical Trials

Ocular Biomarkers for Successful Premium Trifocal Intra-ocular Lenses Implantation

Start date: January 1, 2023
Phase:
Study type: Observational

The purpose of this study is to identify ocular biomarkers that can predict the success of phacoemulsification with bilateral AT LISA try 839MP (Carl Zeiss Meditec AG) implantation to achieve satisfactory post-post-operativly spectacle-free vision. Social, biometric and patient reported outcomes will be evaluated.

NCT ID: NCT05796453 Recruiting - Presbyopia Clinical Trials

Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

Start date: September 19, 2023
Phase: N/A
Study type: Interventional

The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.

NCT ID: NCT05794126 Completed - Presbyopia Clinical Trials

A Clinical Comparison of Two Soft Multifocal Contact Lenses

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The study objective was to gather short-term clinical performance data for two soft multifocal contact lenses.

NCT ID: NCT05763628 Completed - Presbyopia Clinical Trials

Performance Evaluation of Different Daily Disposable Multifocal Contact Lenses

Start date: December 10, 2022
Phase: N/A
Study type: Interventional

The objective of the study is to compare the lens performance of two daily disposable multifocal contact lenses.

NCT ID: NCT05758883 Completed - Cataract Clinical Trials

Post-approval Follow-up Study of the IC-8 Apthera Intraocular Lens (IOL)

Start date: January 12, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate the long-term safety of the IC-8 Apthera intraocular lens (IOL).

NCT ID: NCT05753189 Completed - Presbyopia Clinical Trials

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Start date: February 21, 2023
Phase: Phase 3
Study type: Interventional

Safety Study of the Long-Term Safety of LNZ101 in Presbyopic Subjects

NCT ID: NCT05735990 Completed - Cataract Clinical Trials

Retrospective Clinical Investigation of the Safety and Performance of 640PM Trifocal IOL Implantation in Patients With Cataract and/or Ametropia (Hyperopia, Myopia) and/or Presbyopia

Start date: October 27, 2022
Phase:
Study type: Observational

The clinical investigation objective is to evaluate safety and performance outcomes of trifocal IOL implantation to improve vision in patients with cataract and/or ametropia (hyperopia, myopia) and/or presbyopia. Retrospective data from preoperative status up to 12 month postoperative status will be collected from patients that were implanted with Medicontur's 640PM intraocular lens: - Preoperative status: Preoperative Screening and Baseline - Surgery: IOL implantation - M1: 1 month +/- 2 weeks postoperative follow-up - M3: 3 months +/- 1 month postoperative follow-up - M12: 12 months +/- 3 months postoperative follow-up

NCT ID: NCT05734846 Completed - Presbyopia Clinical Trials

Multifocal Contact Lenses Fitting Methods Comparison

Start date: October 11, 2022
Phase: N/A
Study type: Interventional

The purpose of this study was to compare the clinical performance of two fitting approaches for multifocal contact lenses.

NCT ID: NCT05728944 Completed - Presbyopia Clinical Trials

Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia

CLARITY
Start date: April 24, 2023
Phase: Phase 3
Study type: Interventional

Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia